Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Medically reviewed by Steffini Stalos, DO Bladder cancer occurs when cancerous cells form in the tissues of the bladder, the ...

Beware of fake cancer drugs that have found their way into the booming online business of counterfeit prescription ...

Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with ...

Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of ...

NPC is a malignant tumor that occurs in the epithelium mucosae of the nasopharynx and is one of the most common types of head and neck cancers. According to GLOBOCAN 2022 statistics, the number of ...

1Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 2Department of Surgery, Keio ...

2Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Japan. 6Department of Immunogenomic Medicine, Research ...

A NEW study has unveiled a groundbreaking cancer treatment approach using engineered extracellular vesicles to target both tumor cells and immunosuppressive stromal cells in the tumor microenvironment ...

The final result for recurrence should be identified by histopathological diagnosis (19). Recurrence is defined as any stage or grade of bladder urothelial carcinoma found in the bladder after surgery ...

The study saw 143 patients with suspected bladder cancer randomized into two groups, either going through the usual test called transurethral resection of bladder tumor (TURBT), or an initial MRI ...